Sufentanyl
| Sufentanyl | |
|---|---|
| Salts [] | |
|---|---|
| Sufentanyl citrate | |
| Sufentanyl hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 386.60 g/mol [1] |
| Appearance | Crystals from petroleum ether [1] |
| Melting point | 136.3 [1] |
| Solubility | Soluble [1] |
| Predicted LogP | 4 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C22H30N2O2S |
| IUPAC name | N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide |
| SMILES | CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC |
| InChI | InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3 |
| InChIKey | GGCSSNBKKAUURC-UHFFFAOYSA-N |
| CAS number | 56030-54-7 |
| UNII | AFE2YW0IIZ |
| PubChem CID | 41693 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 162 minutes |
| Duration of action | 30–60 min[3] |
| Routes of administration | Intravenous therapy (IV), intramuscular injection (IM), subcutaneous injection (SQ), epidural, intrathecal, sublingual |
| Toxicity [] | |
|---|---|
| LD50 | Dog: - iv: 10.1-19.5 Guinea: - pig iv: 11.8-13 Mouse: - iv: 16.8-18.7 - parenteral-intravenous: 18.7 mg/kg Rat: - iv: 9.3-12.5 [1] |
Sufentanyl (also known as Chronogesic, Sufentanilum, Zalviso, R-30730, Sufentanilo, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, Ids-ns-001, R 30730 or Sulfentanil) is a anaesthetic and opioid substance of the aniline class.
Chemistry
Salts []
Stereochemistry []
Sufentanyl is achiral.
Druglikeness
Lipinski's rule of five
Sufentanyl matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- anesthetics (N01)
- anesthetics, general (N01A)
- opioid anesthetics (N01AH)
- (N01AH03)
- sufentanil (N01AH03)
MeSH Classification
- analgesics, opioid (M0001068)
- adjuvants, anesthesia (M0001144)
- narcotics (M0014481)
- anesthetics, intravenous (M0027999)
Mechanism of action []
Sufentanil is a synthetic, potent opioid with highly selective binding to μ-opioid receptors. These receptors are widely distributed in the human brain, spinal cord, and other tissues,. In general, opioids decrease cAMP (affecting neural signaling pathways), decrease neurotransmitter release, and cause membrane hyperpolarization, all of which contribute to the relief of painful symptoms. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic neural transmission via G-proteins that activate effector proteins. Binding of the opiate receptor leads to the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP, located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. The release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is then inhibited. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist), also preventing neurotransmitter release. Sufentanil and other opioids open calcium-dependent inwardly rectifying potassium channels, resulting in hyperpolarization and reduced neuronal excitability,. [1]
Medical side effects []
35 side effects listed on drug labels in SIDER 4.1 (sufentanil).
- Pruritus
- Hypotension
- Hypertension
- Muscle rigidity
- Bradycardia
- Dizziness
- Chills
- Euphoric mood
- Body temperature increased
- Miosis
- Urinary incontinence
- Injection site pain
- Anaphylactic shock
- Apnoea
- Arrhythmia
- Bronchospasm
- Confusional state
- Feeling abnormal
- Dermatitis
- Rash
- Headache
- Cardiac arrest
- Hypersensitivity
- Laryngospasm
- Nausea
- Tachycardia
- Erythema
- Urethral disorder
- Urinary tract disorder
- Vomiting
- Urinary retention
- Respiratory depression
- Pulmonary function test decreased
- Hypopnoea
- Somnolence
Indications
- Pain
Subjective effects []
Legal status []
- Australia: Sufentanyl is a Schedule 8.
- Brazil: Sufentanyl is a A1.[4]
- Canada: Sufentanyl is a Schedule I.
- Germany: Sufentanyl is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- United Kingdom: Sufentanyl is a Class A under the "Misuse of Drugs Act 1971".
- United States: Sufentanyl is a Schedule II under the "Controlled Substances Act".[5][6]
- European Union: Sufentanyl is Prescription only.[7]
- Other: Sufentanyl is a SE: Förteckning II In general: ℞ (Prescription only).[8]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 41693, Sufentanyl. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/41693
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Sufentanyl. UNII: AFE2YW0IIZ. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/AFE2YW0IIZ
Shaw LM. The clinical toxicology laboratory : contemporary practice of poisoning evaluation. AACC Press. 2001. https://books.google.com/books?id=pXvFGqz44pYC&pg=PA89
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Sufenta- sufentanil citrate solution. DailyMed. 2 July 2008. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39dc3695-dbf2-4783-b1bf-97237593f1c0
Dsuvia- sufentanil tablet. DailyMed. 18 December 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b580f3d-e3b5-4086-b093-87a980631147
Dzuveo EPAR. European Medicines Agency (EMA). 25 June 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo
Dzuveo, Resoriblett, sublingual 30 mikrog. FASS. 8 February 2024. https://fass.se/health/product/19910906000029/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 09:15:01 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 09:14:57 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 09:14:57 |
| gsrs | ok | 2026-11-20 09:14:58 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014846) | 2026-11-20 09:14:57 |
| kegg | missing (no KEGG DRUG entry) | 2026-11-20 09:15:00 |
| pubchem | ok | 2026-11-20 09:14:56 |
| missing (no r/tripreports posts mention it) | 2026-11-20 09:14:57 | |
| sider | ok | 2026-11-20 09:14:57 |
| structure | ok | 2026-11-20 09:14:57 |
| wikipedia | ok | 2026-11-20 09:14:57 |